EBV genome carrying B lymphocytes that express the nuclear protein EBNA-2 but not LMP-1 Type IIb latency

OncoImmunology

Volumn 2, Issue 2, 2013, Pages

  Klein, Eva ^a   Nagy, Noémi ^a   Rasul, Abu Eahsan ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

Author keywords

EBNA 2; EBV; LMP 1; Type II; Type IIa; Type IIb

Indexed keywords

EPSTEIN BARR VIRUS ANTIGEN 2;

B LYMPHOCYTE; BURKITT LYMPHOMA; CELL EXPANSION; CHRONIC LYMPHATIC LEUKEMIA; EPSTEIN BARR VIRUS; GENE EXPRESSION REGULATION; HUMAN; LATENT VIRUS INFECTION; LYMPHOCYTE PROLIFERATION; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT TRANSFORMATION; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION; REVIEW; VIRUS EXPRESSION; VIRUS GENE; VIRUS GENOME; VIRUS LATENCY;

EID: 84886944081     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.4161/onci.23035     Document Type: Review

References (59)

1. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus receptor of human B lymphocytes is the C3d receptor CR2. Proc Natl Acad Sci U S A 1984; 81:4510-4; PMID:6087328; http://dx.doi.org/10.1073/pnas.81.14.4510.
2. Küppers R. B cells under influence: transformation of B cells by Epstein-Barr virus. Nat Rev Immunol 2003; 3:801-12; PMID:14523386; http://dx.doi.org/10.1038/nri1201.
3. Pope JH, Horne MK, Scott W. Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus. Int J Cancer 1968; 3:857-66; PMID:4894385; http://dx.doi.org/10.1002/ijc.2910030619.
4. Thorley-Lawson DA, Allday MJ. The curious case of the tumour virus: 50 years of Burkitt's lymphoma. Nat Rev Microbiol 2008; 6:913-24; PMID:19008891; http://dx.doi.org/10.1038/nrmicro2015.
5. Young LS, Rickinson AB. Epstein-Barr virus: 40 years on. Nat Rev Cancer 2004; 4:757-68; PMID:15510157; http://dx.doi.org/10.1038/nrc1452.
6. Klein G. Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 1994; 77:791-3; PMID:8004668; http://dx.doi.org/10.1016/0092-8674(94)90125-2.
7. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol 1997; 15:405-31; PMID:9143694; http://dx.doi.org/10.1146/annurev.immunol.15.1.405.
8. Yao QY, Rickinson AB, Epstein MA. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals. Int J Cancer 1985; 35:35-42; PMID:2981780; http://dx.doi.org/10.1002/ijc.2910350107.
9. Khanna R, Moss DJ, Burrows SR. Vaccine strategies against Epstein-Barr virus-associated diseases: lessons from studies on cytotoxic T-cell-mediated immune regulation. Immunol Rev 1999; 170:49-64; PMID:10566141; http://dx.doi.org/10.1111/j.1600-065X.1999.tb01328.x.
10. Pearson G, Dewey F, Klein G, Henle G, Henle W. Relation between neutralization of Epstein-Barr virus and antibodies to cell-membrane antigens-induced by the virus. J Natl Cancer Inst 1970; 45:989-95; PMID:18605425.
11. Tosato G, Magrath IT, Blaese RM. T cell-mediated immunoregulation of Epstein Barr virus- (EBV) induced B lymphocyte activation in EBV-seropositive and EBV-seronegative individuals. J Immunol 1982; 128:575-9; PMID:6274959.
12. Rochford R, Hobbs MV, Garnier JL, Cooper NR, Cannon MJ. Plasmacytoid differentiation of Epstein-Barr virus-transformed B cells in vivo is associated with reduced expression of viral latent genes. Proc Natl Acad Sci U S A 1993; 90:352-6; PMID:8380497; http://dx.doi.org/10.1073/pnas.90.1.352.
13. Kis LL, Salamon D, Persson EK, Nagy N, Scheeren FA, Spits H, et al. IL-21 imposes a type II EBV gene expression on type III and type I B cells by the repression of C- and activation of LMP-1-promoter. Proc Natl Acad Sci U S A 2010; 107:872-7; PMID:20080768; http://dx.doi.org/10.1073/pnas.0912920107.
14. Nagy N, Adori M, Rasul A, Heuts F, Salamon D, Ujvári D, et al. Soluble factors produced by activated CD4+ T cells modulate EBV latency. Proc Natl Acad Sci U S A 2012; 109:1512-7; PMID:22307606; http://dx.doi.org/10.1073/pnas.1120587109.
15. Wendel-Hansen V, Rosén A, Klein G. EBV-transformed lymphoblastoid cell lines down-regulate EBNA in parallel with secretory differentiation. Int J Cancer 1987; 39:404-8; PMID:3546163; http://dx.doi.org/10.1002/ijc.2910390322.
16. Klein E, Kis LL, Klein G. Epstein-Barr virus infection in humans: from harmless to life endangering viruslymphocyte interactions. Oncogene 2007; 26:1297-305; PMID:17322915; http://dx.doi.org/10.1038/sj.onc.1210240.
17. Klein E, Liu A, Claesson HE. Activation of innate immunity by the leukotriene B 4 inhibits EBV induced B-cell transformation in cord-blood derived mononuclear cultures. Immunol Lett 2008; 116:174-7; PMID:18241933; http://dx.doi.org/10.1016/j.imlet.2007.12.006.
18. Teramoto N, Gogolák P, Nagy N, Maeda A, Kvarnung K, Björkholm T, et al. Epstein-Barr virus-infected B-chronic lymphocyte leukemia cells express the virally encoded nuclear proteins but they do not enter the cell cycle. J Hum Virol 2000; 3:125-36; PMID:10881992.
19. Kurth J, Hansmann ML, Rajewsky K, Küppers R. Epstein-Barr virus-infected B cells expanding in germinal centers of infectious mononucleosis patients do not participate in the germinal center reaction. Proc Natl Acad Sci U S A 2003; 100:4730-5; PMID:12665622; http://dx.doi.org/10.1073/pnas.2627966100.
20. Kis LL, Nishikawa J, Takahara M, Nagy N, Matskova L, Takada K, et al. In vitro EBV-infected subline of KMH2, derived from Hodgkin lymphoma, expresses only EBNA-1, while CD40 ligand and IL-4 induce LMP-1 but not EBNA-2. Int J Cancer 2005; 113:937-45; PMID:15514968; http://dx.doi.org/10.1002/ijc.20654.
21. Anastasiadou E, Vaeth S, Cuomo L, Boccellato F, Vincenti S, Cirone M, et al. Epstein-Barr virus infection leads to partial phenotypic reversion of terminally differentiated malignant B cells. Cancer Lett 2009; 284:165-74; PMID:19481340; http://dx.doi. org/10.1016/j.canlet.2009.04.025.
22. Rasul AE, Nagy N, Sohlberg E, ádori M, Claesson HE, Klein G, et al. Simultaneous detection of the two main proliferation driving EBV encoded proteins, EBNA-2 and LMP-1 in single B cells. J Immunol Methods 2012; 385:60-70; PMID:22921685; http://dx.doi.org/10.1016/j.jim.2012.08.008.
23. Hochberg D, Middeldorp JM, Catalina M, Sullivan JL, Luzuriaga K, Thorley-Lawson DA. Demonstration of the Burkitt's lymphoma Epstein-Barr virus phenotype in dividing latently infected memory cells in vivo. Proc Natl Acad Sci U S A 2004; 101:239-44; PMID:14688409; http://dx.doi.org/10.1073/pnas.2237267100.
24. Fåhraeus R, Fu HL, Ernberg I, Finke J, Rowe M, Klein G, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer 1988; 42:329-38; PMID:2843473; http://dx.doi.org/10.1002/ijc.2910420305.
25. Deacon EM, Pallesen G, Niedobitek G, Crocker J, Brooks L, Rickinson AB, et al. Epstein-Barr virus and Hodgkin's disease: transcriptional analysis of virus latency in the malignant cells. J Exp Med 1993; 177:339-49; PMID:8381153; http://dx.doi.org/10.1084/jem.177.2.339.
26. Pallesen G, Hamilton-Dutoit SJ, Rowe M, Young LS. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease. Lance 1991; 337:320-2; PMID:1671232; http://dx.doi.org/10.1016/0140-6736(91)90943-J.
27. Staratschek-Jox A, Wolf J, Diehl V. Hodgkin's disease. In: Masters JRW, Palsson B, ed. Human cell culture Vol 3 Lymphoma and leukemia cell lines: Dordrecht: Kluwer Academic Press, 2000:339-53.
28. Vockerodt M, Belge G, Kube D, Irsch J, Siebert R, Tesch H, et al. An unbalanced translocation involving chromosome 14 is the probable cause for loss of potentially functional rearranged immunoglobulin heavy chain genes in the Epstein-Barr virus-positive Hodgkin's lymphoma-derived cell line L591. Br J Haematol 2002; 119:640-6; PMID:12437638; http://dx.doi.org/10.1046/j.1365-2141.2002.03894.x.
29. Küppers R. The biology of Hodgkin's lymphoma. Nat Rev Cancer 2009; 9:15-27; PMID:19078975; http://dx.doi.org/10.1038/nrc2542.
30. Hjalgrim H, Smedby KE, Rostgaard K, Molin D, Hamilton-Dutoit S, Chang ET, et al. Infectious mononucleosis, childhood social environment, and risk of Hodgkin lymphoma. Cancer Res 2007; 67:2382-8; PMID:17332371; http://dx.doi.org/10.1158/0008-5472.CAN-06-3566.
31. Bräuninger A, Schmitz R, Bechtel D, Renné C, Hansmann ML, Küppers R. Molecular biology of Hodgkin's and Reed/Sternberg cells in Hodgkin's lymphoma. Int J Cancer 2006; 118:1853-61; PMID:16385563; http://dx.doi.org/10.1002/ijc.21716.
32. Tierney R, Kirby H, Nagra J, Rickinson A, Bell A. The Epstein-Barr virus promoter initiating B-cell transformation is activated by RFX proteins and the B-cell-specific activator protein BSAP/Pax5. J Virol 2000; 74:10458-67; PMID:11044090; http://dx.doi.org/10.1128/JVI.74.22.10458-10467.2000.
33. Contreras-Brodin B, Karlsson A, Nilsson T, Rymo L, Klein G. B cell-specific activation of the Epstein-Barr virus-encoded C promoter compared with the wide-range activation of the W promoter. J Gen Virol 1996; 77:1159-62; PMID:8683201; http://dx.doi.org/10.1099/0022-1317-77-6-1159.
34. Doyle MG, Catovsky D, Crawford DH. Infection of leukaemic B lymphocytes by Epstein Barr virus. Leukemia 1993; 7:1858-64; PMID:8231253.
35. Walls EV, Doyle MG, Patel KK, Allday MJ, Catovsky D, Crawford DH. Activation and immortalization of leukaemic B cells by Epstein-Barr virus. Int J Cancer 1989; 44:846-53; PMID:2555307; http://dx.doi.org/10.1002/ijc.2910440517.
36. Rickinson AB, Finerty S, Epstein MA. Interaction of Epstein-Barr virus with leukaemic B cells in vitro. I. Abortive infection and rare cell line establishment from chronic lymphocytic leukaemic cells. Clin Exp Immunol 1982; 50:347-54; PMID:6295671.
37. Takada K, Yamamoto K, Osato T. Analysis of the transformation of human lymphocytes by Epstein-Barr virus. II. Abortive response of leukemic cells to the transforming virus. Intervirology 1980; 13:223-31; PMID:6248483; http://dx.doi.org/10.1159/000149129.
38. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999; 17:399-408; PMID:10458259.
39. Klein E, Nagy N. Restricted expression of EBV encoded proteins in in vitro infected CLL cells. Semin Cancer Biol 2010; 20:410-5; PMID:21034831; http://dx.doi.org/10.1016/j.semcancer.2010.10.013.
40. Kanzler H, Küppers R, Helmes S, Wacker HH, Chott A, Hansmann ML, et al. Hodgkin and Reed-Sternberglike cells in B-cell chronic lymphocytic leukemia represent the outgrowth of single germinal-center B-cell-derived clones: potential precursors of Hodgkin and Reed-Sternberg cells in Hodgkin's disease. Blood 2000; 95:1023-31; PMID:10648418.
41. Tsimberidou AM, O'Brien S, Kantarjian HM, Koller C, Hagemeister FB, Fayad L, et al. Hodgkin transformation of chronic lymphocytic leukemia: the M. D. Anderson Cancer Center experience. Cancer 2006; 107:1294-302; PMID:16902984; http://dx.doi.org/10.1002/cncr.22121.
42. Avila-Cariño J, Andersson J, Mellstedt H, Klein E. B-CLL cells experimentally infected with EBV enter DNA synthesis, produce cytokines and stimulate T-lymphocytes. Immunol Lett 1996; 54:45-52; PMID:9030981; http://dx.doi.org/10.1016/S0165-2478(96)02643-0.
43. Maeda A, Bandobashi K, Nagy N, Teramoto N, Gogolák P, Pokrovskaja K, et al. Epstein-barr virus can infect B-chronic lymphocytic leukemia cells but it does not orchestrate the cell cycle regulatory proteins. J Hum Virol 2001; 4:227-37; PMID:11907380.
44. Rosén A, Bergh AC, Gogok P, Evaldsson C, Myhrinder AL, Hellqvist E, et al. Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection. Oncoimmunology 2012; 1:18-27; PMID:22720208; http://dx.doi.org/10.4161/onci.1.1.18400.
45. Tomita Y, Avila-Cariño J, Yamamoto K, Mellstedt H, Klein E. Recognition of B-CLL cells experimentally infected with EBV by autologous T lymphocytes. Immunol Lett 1998; 60:73-9; PMID:9580478; http://dx.doi.org/10.1016/S0165-2478(97)00142-9.
46. Lewin N, Minarovits J, Weber G, Ehlin-Henriksson B, Wen T, Mellstedt H, et al. Clonality and methylation status of the Epstein-Barr virus (EBV) genomes in in vivo-infected EBV-carrying chronic lymphocytic leukemia (CLL) cell lines. Int J Cancer 1991; 48:62-6; PMID:1850384; http://dx.doi.org/10.1002/ijc.2910480112.
47. Stacchini A, Aragno M, Vallario A, Alfarano A, Circosta P, Gottardi D, et al. MEC1 and MEC2: two new cell lines derived from B-chronic lymphocytic leukaemia in prolymphocytoid transformation. Leuk Res 1999; 23:127-36; PMID:10071128; http://dx.doi.org/10.1016/S0145-2126(98)00154-4.
48. Nagy N, Klein G, Klein E. To the genesis of Burkitt lymphoma: regulation of apoptosis by EBNA-1 and SAP may determine the fate of Ig-myc translocation carrying B lymphocytes. Semin Cancer Biol 2009; 19:407-10; PMID:19874894; http://dx.doi.org/10.1016/j.semcancer.2009.10.001.
49. Kennedy G, Komano J, Sugden B. Epstein-Barr virus provides a survival factor to Burkitt's lymphomas. Proc Natl Acad Sci U S A 2003; 100:14269-74; PMID:14603034; http://dx.doi.org/10.1073/pnas.2336099100.
50. Allday MJ. How does Epstein-Barr virus (EBV) complement the activation of Myc in the pathogenesis of Burkitt's lymphoma? Semin Cancer Biol 2009; 19:366-76; PMID:19635566; http://dx.doi.org/10.1016/j.semcancer.2009.07.007.
51. Kelly GL, Milner AE, Baldwin GS, Bell AI, Rickinson AB. Three restricted forms of Epstein-Barr virus latency counteracting apoptosis in c-myc-expressing Burkitt lymphoma cells. Proc Natl Acad Sci U S A 2006; 103:14935-40; PMID:17001014; http://dx.doi.org/10.1073/pnas.0509988103.
52. Brink AA, Dukers DF, van den Brule AJ, Oudejans JJ, Middeldorp JM, Meijer CJ, et al. Presence of Epstein-Barr virus latency type III at the single cell level in post-transplantation lymphoproliferative disorders and AIDS related lymphomas. J Clin Pathol 1997; 50:911-8; PMID:9462239; http://dx.doi.org/10.1136/jcp.50.11.911.
53. Kurth J, Spieker T, Wustrow J, Strickler GJ, Hansmann LM, Rajewsky K, et al. EBV-infected B cells in infectious mononucleosis: viral strategies for spreading in the B cell compartment and establishing latency. Immunity 2000; 13:485-95; PMID:11070167; http://dx.doi.org/10.1016/S1074-7613(00)00048-0.
54. Niedobitek G, Agathanggelou A, Herbst H, Whitehead L, Wright DH, Young LS. Epstein-Barr virus (EBV) infection in infectious mononucleosis: virus latency, replication and phenotype of EBV-infected cells. J Pathol 1997; 182:151-9; PMID:9274524; http://dx.doi.org/10.1002/(SICI)1096-9896(199706)182:2<151::AIDPATH824> 3.0.CO;2-3.
55. Oudejans JJ, Jiwa M, van den Brule AJ, Grässer FA, Horstman A, Vos W, et al. Detection of heterogeneous Epstein-Barr virus gene expression patterns within individual post-transplantation lymphoproliferative disorders. Am J Pathol 1995; 147:923-33; PMID:7573368.
56. Cocco M, Bellan C, Tussiwand R, Corti D, Traggiai E, Lazzi S, et al. CD34+ cord blood cell-transplanted Rag2-/- gamma(c)-/- mice as a model for Epstein-Barr virus infection. Am J Pathol 2008; 173:1369-78; PMID:18845836; http://dx.doi.org/10.2353/ajpath.2008.071186.
57. Ma SD, Hegde S, Young KH, Sullivan R, Rajesh D, Zhou Y, et al. A new model of Epstein-Barr virus infection reveals an important role for early lytic viral protein expression in the development of lymphomas. J Virol 2011; 85:165-77; PMID:20980506; http://dx.doi.org/10.1128/JVI.01512-10.
58. Yajima M, Imadome K, Nakagawa A, Watanabe S, Terashima K, Nakamura H, et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis 2008; 198:673-82; PMID:18627269; http://dx.doi.org/10.1086/590502.
59. Islas-Ohlmayer M, Padgett-Thomas A, Domiati-Saad R, Melkus MW, Cravens PD, Martin MdelP, et al. Experimental infection of NOD/SCID mice reconstituted with human CD34+ cells with Epstein-Barr virus. J Virol 2004; 78:13891-900; PMID:15564497; http://dx.doi.org/10.1128/JVI.78.24.13891-13900.2004.